|  |
| --- |
| **Supplementary Table 1-Soy isoflavone intake and treatment-related symptoms among Chinese American and non-Hispanic White breast cancer survivors** |
|  | **Menopausal symptomsb** | **Fatigue** | **Joint problemsc** | **Hair loss or thinning** | **Memory loss** |
|  | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d |
| IsoflavonesaOverall No intake  >0 - <6.3 mg/day ≥6.3 mg/day P-trendNon-Hispanic White No intake  >0 - <6.3 mg/day ≥6.3 mg/day P-trendChinese American No intake  >0 - <6.3 mg/day ≥6.3 mg/day P-trend | 66/3874/5563/6951/2238/2419/1915/1636/3144/55 | Reference0.50 (0.25, 0.99)0.48 (0.23, 0.96)0.05Reference0.42 (0.15, 1.19)0.24 (0.07, 0.78)0.01Reference0.52 (0.17, 1.59)0.61 (0.21, 1.79)0.55 | 59/4571/5866/6639/3430/3211/2720/1141/2655/39 | Reference0.62 (0.33, 1.16)0.43 (0.22, 0.84)0.01Reference0.58 (0.25, 1.37)0.18 (0.06, 0.52)0.002Reference0.78 (0.26, 2.30)0.77 (0.27, 2.15)0.66 | 54/5067/6265/6735/3827/3514/2419/1240/2751/43 | Reference0.80 (0.43, 1.46)0.56 (0.30, 1.06)0.07Reference0.56 (0.23, 1.34)0.40 (0.15, 1.06)0.06Reference1.14 (0.42, 3.12)0.75 (0.28, 1.96)0.38 | 41/6457/7247/8423/5024/3812/2618/1333/3435/58 | Reference0.90 (0.49, 1.68)0.65 (0.34, 1.25)0.19Reference1.02 (0.41, 2.51)0.72 (0.26, 1.96)0.56Reference0.56 (0.20, 1.52)0.46 (0.17, 1.22)0.14 | 33/7142/8739/9315/5815/477/3118/1327/4032/62 | Reference0.77 (0.40, 1.48)0.58 (0.29, 1.15)0.12Reference1.14 (0.45, 2.88)0.75 (0.25, 2.25)0.69Reference0.50 (0.17, 1.42)0.41 (0.15, 1.14)0.12 |
| aTertiles.bMenopausal symptoms: Hot flashes or night/cold sweats, vaginal dryness/pain with intercourse, vaginal discharge.cJoint problems: muscle pain, joint stiffness, joint pain, bone thinning.dMultivariable logistic regression adjusted for age (continuous), ethnicity (Chinese American, non-Hispanic White), menopausal status (premenopause, treatment induced menopause, perimenopause, postmenopause), BMI (continuous), physical activity (active, minimally active, inactive), endocrine therapy (none, tamoxifen, aromatase inhibitor), time since diagnosis (<24 months, 24-36 months, ≥36 months), and cancer stage (0, I, II, III).  |

|  |
| --- |
| **Supplementary Table 2-Glucosinoate intake and treatment-related symptoms among Chinese American and non-Hispanic White breast cancer survivors** |
|  | **Menopausal symptomsb** | **Fatigue** | **Joint problemsc** | **Hair loss or thinning** | **Memory loss** |
|  | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d |
| GlucosinolatesaOverall ≤20.4 mg/day >20.4 - <50.1 mg/day >50.1 mg/dayP-trendNon-Hispanic White ≤20.4 mg/day >20.4 - <50.1 mg/day >50.1 mg/dayP-trendChinese American ≤20.41mg/day >20.4 - <50.1 mg/day >50.1 mg/dayP-trend | 71/5069/5163/6145/3535/3028/2026/2534/3135/41 | Reference0.80 (0.42, 1.53)0.57 (0.30, 1.10)0.10Reference1.49 (0.53, 4.13)0.75 (0.26, 2.17)0.67Reference0.72 (0.27, 1.86)0.48 (0.18, 1.22)0.12 | 60/6168/5268/5630/4029/2621/2730/2139/2647/29 | Reference1.11 (0.62, 2.01)1.14 (0.63, 2.07)0.65Reference1.41 (0.59, 3.35)0.99 (0.41, 2.40)0.93Reference0.92 (0.37, 2.31)1.10 (0.44, 2.72)0.81 | 59/6261/5966/5828/4224/3124/2431/2037/2842/34 | Reference0.90 (0.51, 1.58)1.13 (0.63, 2.01)0.69Reference0.89 (0.37, 2.13)1.15 (0.47, 2.76)0.80Reference1.16 (0.50, 2.67)1.20 (0.51, 2.77)0.68 | 46/7555/6544/7918/5223/3218/3028/2332/3326/49 | Reference1.11 (0.62, 1.98)0.74 (0.41, 1.36)0.37Reference2.13 (0.84, 5.39)1.59 (0.60, 4.21)0.28Reference0.61 (0.26, 1.53)0.30 (0.12, 0.73)0.007 | 34/8739/8141/839/6113/4215/3325/2626/3926/50 | Reference0.98 (0.53, 1.83)1.09 (0.58, 2.05)0.77Reference1.66 (0.59, 4.69)3.09 (1.11, 8.63)0.03Reference0.60 (0.25, 1.44)0.50 (0.20, 1.23)0.14 |
| aTertiles.bMenopausal symptoms: Hot flashes or night/cold sweats, vaginal dryness/pain with intercourse, vaginal discharge.cJoint problems: muscle pain, joint stiffness, joint pain, bone thinning.dMultivariable logistic regression adjusted for age (continuous), ethnicity (Chinese American, non-Hispanic White), menopausal status (premenopause, treatment induced menopause, perimenopause, postmenopause), BMI (continuous), physical activity (active, minimally active, inactive), endocrine therapy (none, tamoxifen, aromatase inhibitor), time since diagnosis (<24 months, 24-36 months, ≥36 months), and cancer stage (0, I, II, III). |

|  |
| --- |
| **Supplementary Table 3-Cruciferous vegetable and soy intake, endocrine therapy and treatment-related symptoms among Chinese American and non-Hispanic White breast cancer survivors** |
|  | **Menopausal symptomsb** | **Fatigue** | **Joint problemsc** | **Hair loss or thinning** | **Memory loss** |
|  | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d | NYes/No | Multivariate OR (95% CI)d |
| Soy ProductsaNon-Users No intake >0 - <24.0 g/day ≥24.0 g/dayP-trendTamoxifen  No intake >0 - <24.0 g/day ≥24.0 g/dayP-trendAromatase Inhibitor  No intake >0 - <24.0 g/day ≥24.0 g/dayP-trendP-interaction5Cruciferous vegetables1Non-Users <33.0 g/day ≥33.0 - <70.8 g/day ≥70.8 g/dayP-trendTamoxifen <33.0 g/day ≥33.0 - <70.8 g/day ≥70.8 g/dayP-trendAromatase Inhibitor <33.0 g/day ≥33.0 - <70.8 g/day ≥70.8 g/dayP-trendP-interaction5 | 21/2122/3016/3822/541/1233/1223/1211/1514/1618/3024/2517/3433/934/729/1421/1015/1512/18 | Reference0.78 (0.25, 2.41)0.46 (0.15, 1.35)0.15Reference0.30 (0.05, 1.87)0.78 (0.12, 4.85)0.90Reference0.22 (0.05, 0.87)0.66 (0.16, 2.75)0.430.51Reference2.04 (0.70, 5.90)0.86 (0.28, 2.62)0.75Reference1.38 (0.28, 6.63)0.75 (0.17, 3.34)0.66Reference0.22 (0.05, 0.94)0.13 (0.02, 0.62)0.010.20 | 25/1722/3020/3412/1537/1628/1822/1313/1317/1320/2821/2826/2522/2028/1327/1618/1316/1418/12 | Reference0.42 (0.14, 1.28)0.21 (0.06, 0.65)0.007Reference1.53 (0.43, 5.45)1.26 (0.32, 4.87)0.81Reference0.25 (0.06, 1.07)0.28 (0.06, 1.27)0.080.39Reference1.20 (0.41, 3.48)1.58 (0.56, 4.43)0.38Reference1.42 (0.45, 4.47)2.07 (0.62, 6.91)0.23Reference0.58 (0.15, 2.23)0.48 (0.12, 1.96)0.300.73 | 21/2126/2621/339/1828/2525/2124/1114/1218/1221/2724/2523/2821/2119/2222/2117/1418/1221/9 | Reference0.51 (0.15, 1.69)0.31 (0.10, 0.97)0.05Reference1.65 (0.50, 5.48)1.87 (0.52, 6.73)0.37Reference0.14 (0.02, 0.75)0.16 (0.03, 0.85)0.030.39Reference0.97 (0.31, 3.00)0.48 (0.15, 1.52)0.20Reference0.63 (0.21, 1.85)1.02 (0.34, 3.03)0.90Reference0.91 (0.22, 3.64)0.99 (0.22, 4.43)0.980.41 | 18/2421/3116/388/1925/2820/2515/2012/1410/2018/3021/2816/3515/2720/2118/2412/1915/1510/20 | Reference0.71 (0.24, 2.10)0.53 (0.19, 1.49)0.23Reference0.95 (0.26, 3.43)1.30 (0.33, 5.14)0.64Reference0.69 (0.17, 2.76)0.36 (0.08, 1.46)0.160.15Reference1.25 (0.45, 3.41)0.37 (0.12, 1.10)0.08Reference1.43 (0.44, 4.65)1.09 (0.33, 3.59)0.91Reference1.68 (0.41, 6.82)0.29 (0.06, 1.37)0.140.39 | 14/2817/3512/425/2220/3315/3114/216/2011/1911/3714/3518/339/3319/2212/3110/219/2112/18 | Reference0.85 (0.27, 2.70)0.41 (0.12, 1.30)0.12Reference1.97 (0.51, 7.61)1.25 (0.30, 5.23)0.98Reference0.10 (0.01, 0.60)0.35 (0.07, 1.57)0.120.89Reference1.03 (0.34, 3.16)0.99 (0.33, 2.95)0.98Reference2.65 (0.78, 8.91)1.69 (0.48, 5.88)0.51Reference0.31 (0.06, 1.47)0.41 (0.09, 1.83)0.270.68 |
| aTertiles.bMenopausal symptoms: Hot flashes or night/cold sweats, vaginal dryness/pain with intercourse, vaginal discharge.cJoint problems: muscle pain, joint stiffness, joint pain, bone thinning.dMultivariable logistic regression adjusted for age (continuous), ethnicity (Chinese American, non-Hispanic White), menopausal status (premenopause, treatment induced menopause, perimenopause, postmenopause), BMI (continuous), physical activity (active, minimally active, inactive), endocrine therapy (none, tamoxifen, aromatase inhibitor), time since diagnosis (<24 months, 24-36 months, ≥36 months), and cancer stage (0, I, II, III).5Logistic regression model additionally including cross-product interaction term for food item and endocrine therapy usage. |